Brolucizumab for Diabetic Macular Edema in Participants With/Without Prior Anti-VEGF Exposure: KINGFISHER Study Post Hoc Analysis

OBJECTIVE: To evaluate visual and anatomical outcomes of brolucizumab 6 mg versus aflibercept 2 mg in subgroups of participants with/without prior anti-vascular endothelial growth factor treatment for diabetic macular edema in the KINGFISHER study. DESIGN: Post hoc analysis of the KINGFISHER study PARTICIPANTS: Of 517 participants randomized, 370 (71.6%) treatment-naive (brolucizumab 6 mg [n=251]; aflibercept 2 mg [n=119]) and 147 (28.4%) …